Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

8.350 +0.140 (+1.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,766
Open 8.230
Bid (Size) 7.700 (2)
Ask (Size) 8.740 (1)
Prev. Close 8.210
Today's Range 8.170 - 8.760
52wk Range 6.575 - 16.63
Shares Outstanding 75,480,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire

Performance

YTD
-26.04%
-26.04%
1 Month
+1.95%
+1.95%
3 Month
+0.48%
+0.48%
6 Month
-10.31%
-10.31%
1 Year
+25.38%
+25.38%

More News

Read More
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
ETNB Stock Earnings: 89bio Beats EPS for Q2 2024
Via InvestorPlace
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
Via InvestorPlace
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Francis Sarena as Chief Operating Officer
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Second Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Via Benzinga
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
Via Investor's Business Daily
The Week Ahead: What's Next
Via Talk Markets
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
From 89bio, Inc.
Via GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.